news
CHMP meeting highlights – May 2025
The EMA’s committee has granted positive opinions for ten new treatments, including medicines for oncology indications and rare diseases.
List view / Grid view
gastroenteropancreatic neuroendocrine tumours (GEP-NETs)
article
The future of targeted alpha therapy development and manufacture
Following the first industrial-scale facility for targeted alpha therapy (TAT) production in Europe beginning construction, in this exclusive Q&A, Julien Dodet, CEO of Orano Med, elaborates on the key trends in radioligand therapeutics and why TATs hold significant advantages as cancer treatments.
news
Lilly agrees $1.4 billion radiopharma acquisition
Two late-stage radioligand therapies for oncological indications are planned to be developed through an acquisition agreement between Eli Lilly and POINT Biopharma Global.
news
Radioligand therapy demonstrates novel first line benefit
Novartis’ radioligand therapy (RLT) is the first to demonstrate clinically meaningful benefit in a first line setting.
news
Radionuclide alpha therapy shows promising survival rates in neuroendocrine tumour patients
A targeted radionuclide alpha therapy, 225Ac-DOTATATE, has been shown to have long-term anti-tumour effects in patients with advanced gastroenteropancreatic neuroendocrine tumours (GEP-NETs).
news
FDA approves Lutathera for somatostatin receptor-positive GEP-NETs
The FDA has approved Lutathera for the treatment of a type of cancer that affects the pancreas the gastrointestinal tract...
